EOS Intelligence

Open Banking Sparking a Wave of Innovation in Financial Services

21/11/2024by EOS Intelligence

The adoption of open banking is leading to innovation across financial solutions such as account-to-account payments (A2A), personal finance management (PFM) apps, embedded finance, and banking-as-a-service (BaaS) by enabling real-time...

Continuous Glucose Monitoring Devices: Overcoming Barriers in LMICs

12/11/2024by EOS Intelligence

The rising prevalence of diabetes in low- and middle-income countries (LMICs) underscores the need for advanced diabetes management solutions. Continuous glucose monitoring (CGM) systems are highly valuable but face limited...

The Future of Diabetes Care: Key Innovations in the Continuous Glucose Monitoring

21/10/2024by EOS Intelligence

Continuous glucose monitors (CGM) represent a disruptive innovation that has transformed the diabetes management landscape. In recent years, the CGM market has seen remarkable growth, becoming an integral part of...

NVIDIA’s Meteoric Rise: Can the AI Chip Giant Sustain Its Dominance?

17/10/2024by EOS Intelligence

NVIDIA has grown exponentially in recent years. The company made significant strides as an early entrant into the AI chip market, becoming the sector’s leading company. In July 2024, NVIDIA’s...

Mind over Matter How Non-invasive Neuromodulation Is Becoming the Future of Pain Management by EOS Intelligence

Mind over Matter: How Non-invasive Neuromodulation Is Becoming the Future of Pain Management and Beyond

08/10/2024by EOS Intelligence

Scientists have been researching the possibility of using electrical impulses to treat many health conditions. The starting point was the introduction of the first TENS (transcutaneous electrical nerve stimulation) device...

New Directions in Alzheimer’s Diagnostics: Will Blood Tests Replace CSF and PET?

30/09/2024by EOS Intelligence

Around three-fourths of dementia cases continue to remain undiagnosed even though the incidence of Alzheimer’s disease (AD) is rapidly growing across the globe. AD affects about 60-80% of dementia patients...

Phase 3 Drug Candidates – A Ray of Hope in Alzheimer’s Disease Bleak Treatment Landscape?

26/09/2024by EOS Intelligence

Many biopharmaceutical companies, such as AriBio, Annovis Bio, Athira Pharma, Cassava Sciences, and Alzheon, specializing in treating neurodegenerative diseases, are developing drugs for Alzheimer’s disease (AD) that are currently in...

Pharma Companies Navigate Their Way through Ac-225 amidst Supply Constraints

19/09/2024by EOS Intelligence

Pharma companies have been increasingly investing in developing targeted alpha therapies for cancer treatment, using alpha-emitting isotopes such as Ac-225. However, the current supply for Ac-225 is limited, and thus,...

Who We Are

Connect With Us

Work With EOS